Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma
Sirolimus is an effective oral treatment for pediatric patients with lymphangioma. The present clinical study in 15 children (0.12–16.39 years of age) examines the effects of underlying factors on sirolimus concentrations through application of a population pharmacokinetic model. Using Monte Carlo s...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-11-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.668952/full |
| _version_ | 1819199815642251264 |
|---|---|
| author | Xiao Chen Dongdong Wang Guangfei Wang Yidie Huang Xin Yu Jinmiao Lu Xiaowen Zhai Hong Xu Zhiping Li |
| author_facet | Xiao Chen Dongdong Wang Guangfei Wang Yidie Huang Xin Yu Jinmiao Lu Xiaowen Zhai Hong Xu Zhiping Li |
| author_sort | Xiao Chen |
| collection | DOAJ |
| description | Sirolimus is an effective oral treatment for pediatric patients with lymphangioma. The present clinical study in 15 children (0.12–16.39 years of age) examines the effects of underlying factors on sirolimus concentrations through application of a population pharmacokinetic model. Using Monte Carlo simulation, an initial dose regimen for sirolimus in pediatric patients with lymphangioma is presented. It is found that the lower the body weight, the higher the clearance rate and sirolimus clearances are 0.31–0.17 L/h/kg in pediatric patients with lymphangioma whose weights are 5–60 kg, respectively. The doses of sirolimus, 0.07, 0.06, 0.05 mg/kg/day are recommended for weights of 5–10, 10–24.5 and 24.5–60 kg in children with lymphangioma. This study is the first to establish a population pharmacokinetic model for sirolimus and to recommend initial doses in pediatric patients with lymphangioma. Large scale, prospective studies are needed in the future. |
| first_indexed | 2024-12-23T03:22:20Z |
| format | Article |
| id | doaj.art-c13e6d3278264d2a93c807a78e5b9a71 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-23T03:22:20Z |
| publishDate | 2021-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-c13e6d3278264d2a93c807a78e5b9a712022-12-21T18:01:58ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-11-011210.3389/fphar.2021.668952668952Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With LymphangiomaXiao Chen0Dongdong Wang1Guangfei Wang2Yidie Huang3Xin Yu4Jinmiao Lu5Xiaowen Zhai6Hong Xu7Zhiping Li8Department of Pharmacy, National Children’s Medical Center, Children’s Hospital of Fudan University, Shanghai, ChinaDepartment of Pharmacy, National Children’s Medical Center, Children’s Hospital of Fudan University, Shanghai, ChinaDepartment of Pharmacy, National Children’s Medical Center, Children’s Hospital of Fudan University, Shanghai, ChinaDepartment of Pharmacy, National Children’s Medical Center, Children’s Hospital of Fudan University, Shanghai, ChinaDepartment of Pharmacy, National Children’s Medical Center, Children’s Hospital of Fudan University, Shanghai, ChinaDepartment of Pharmacy, National Children’s Medical Center, Children’s Hospital of Fudan University, Shanghai, ChinaDepartment of Hematology and Oncology, National Children’s Medical Center, Children’s Hospital of Fudan University, Shanghai, ChinaDepartment of Nephrology, National Children’s Medical Center, Children’s Hospital of Fudan University, Shanghai, ChinaDepartment of Pharmacy, National Children’s Medical Center, Children’s Hospital of Fudan University, Shanghai, ChinaSirolimus is an effective oral treatment for pediatric patients with lymphangioma. The present clinical study in 15 children (0.12–16.39 years of age) examines the effects of underlying factors on sirolimus concentrations through application of a population pharmacokinetic model. Using Monte Carlo simulation, an initial dose regimen for sirolimus in pediatric patients with lymphangioma is presented. It is found that the lower the body weight, the higher the clearance rate and sirolimus clearances are 0.31–0.17 L/h/kg in pediatric patients with lymphangioma whose weights are 5–60 kg, respectively. The doses of sirolimus, 0.07, 0.06, 0.05 mg/kg/day are recommended for weights of 5–10, 10–24.5 and 24.5–60 kg in children with lymphangioma. This study is the first to establish a population pharmacokinetic model for sirolimus and to recommend initial doses in pediatric patients with lymphangioma. Large scale, prospective studies are needed in the future.https://www.frontiersin.org/articles/10.3389/fphar.2021.668952/fulloptimizationinitial dose regimensirolimuspediatriclymphangioma |
| spellingShingle | Xiao Chen Dongdong Wang Guangfei Wang Yidie Huang Xin Yu Jinmiao Lu Xiaowen Zhai Hong Xu Zhiping Li Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma Frontiers in Pharmacology optimization initial dose regimen sirolimus pediatric lymphangioma |
| title | Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma |
| title_full | Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma |
| title_fullStr | Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma |
| title_full_unstemmed | Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma |
| title_short | Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma |
| title_sort | optimization of initial dose regimen for sirolimus in pediatric patients with lymphangioma |
| topic | optimization initial dose regimen sirolimus pediatric lymphangioma |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2021.668952/full |
| work_keys_str_mv | AT xiaochen optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma AT dongdongwang optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma AT guangfeiwang optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma AT yidiehuang optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma AT xinyu optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma AT jinmiaolu optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma AT xiaowenzhai optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma AT hongxu optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma AT zhipingli optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma |